Salvia plebeia R.Br. inhibits signal transduction of IL-6 and prevents ovariectomy-induced bone loss by suppressing osteoclastogenesis

[1]  H. Moon,et al.  Role of C-reactive protein in osteoclastogenesis in rheumatoid arthritis , 2015, Arthritis Research & Therapy.

[2]  Eugenia G. Giannopoulou,et al.  RBP-J imposes a requirement for ITAM-mediated costimulation of osteoclastogenesis. , 2014, The Journal of clinical investigation.

[3]  Sang-Hyun Kim,et al.  Salvia plebeia suppresses atopic dermatitis-like skin lesions. , 2014, The American journal of Chinese medicine.

[4]  Xiaoying Qin,et al.  Four new eudesmane-type sesquiterpenes from the basal leaves of Salvia plebeia R. Br. , 2014, Fitoterapia.

[5]  T. Kodama,et al.  The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss. , 2014, Bone.

[6]  Hong-Hee Kim,et al.  Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice. , 2013, Biochemical pharmacology.

[7]  Y. Soh,et al.  Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways. , 2013, European journal of pharmacology.

[8]  E. Miot-Noirault,et al.  The Polyphenol Fisetin Protects Bone by Repressing NF-κB and MKP-1-Dependent Signaling Pathways in Osteoclasts , 2013, PloS one.

[9]  Jinxia Zhao,et al.  AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis. , 2013, Biochemical and biophysical research communications.

[10]  Hong-Hee Kim,et al.  Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos. , 2012, Bone.

[11]  Ji-Young Kim,et al.  RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation. , 2011, The Biochemical journal.

[12]  J. Berthelot,et al.  Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. , 2010, Joint, bone, spine : revue du rhumatisme.

[13]  B. Cha,et al.  Inhibitory effect of luteolin on osteoclast differentiation and function , 2009, Cytotechnology.

[14]  J. Penninger,et al.  RANK/RANKL: Regulators of Immune Responses and Bone Physiology , 2008, Annals of the New York Academy of Sciences.

[15]  Zheng-Tao Wang,et al.  Chemical fingerprint and quantitative analysis of Salvia plebeia R.Br. by high-performance liquid chromatography. , 2008, Journal of pharmaceutical and biomedical analysis.

[16]  C. Bäckesjö,et al.  IL-6 receptor expression and IL-6 effects change during osteoblast differentiation. , 2008, Cytokine.

[17]  A. Kavanaugh,et al.  Medical Management of Rheumatoid Arthritis , 2007 .

[18]  T. Hentunen,et al.  Differentiation of osteoblasts and osteocytes from mesenchymal stem cells. , 2008, Current stem cell research & therapy.

[19]  K. Ishihara,et al.  Interleukin-6 Directly Inhibits Osteoclast Differentiation by Suppressing Receptor Activator of NF-κB Signaling Pathways* , 2008, Journal of Biological Chemistry.

[20]  E. Williamson,et al.  Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health , 2007, Phytotherapy research : PTR.

[21]  M. Seibel.  Biochemical markers of bone turnover: part I: biochemistry and variability. , 2005, The Clinical biochemist. Reviews.

[22]  N. Morrison,et al.  MCP-1 Is Induced by Receptor Activator of Nuclear Factor-κB Ligand, Promotes Human Osteoclast Fusion, and Rescues Granulocyte Macrophage Colony-stimulating Factor Suppression of Osteoclast Formation* , 2005, Journal of Biological Chemistry.

[23]  T. Martin,et al.  Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. , 2004, The Journal of clinical investigation.

[24]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[25]  I. Wicks,et al.  The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. , 2003, Arthritis and rheumatism.

[26]  N. Athanasou,et al.  Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. , 2002, Bone.

[27]  Hiroshi Takayanagi,et al.  Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. , 2002, Developmental cell.

[28]  H. Oh,et al.  Vigna angularis inhibits IL-6-induced cellular signalling and ameliorates collagen-induced arthritis. , 2014, Rheumatology.

[29]  G. Fernandes,et al.  Alternative therapies for the prevention and treatment of osteoporosis. , 2012, Nutrition reviews.

[30]  Seok-Geun Lee,et al.  Manassantin A and B from Saururus chinensis inhibit interleukin-6-induced signal transducer and activator of transcription 3 activation in Hep3B cells. , 2011, Journal of pharmacological sciences.

[31]  J. Hong,et al.  The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. , 2011, The Journal of nutritional biochemistry.

[32]  Teiji Wada,et al.  RANKL-RANK signaling in osteoclastogenesis and bone disease. , 2006, Trends in molecular medicine.

[33]  T. Kishimoto,et al.  IL-6 Receptor , 1990 .